2023-06-28 12:43:06 ET
Atossa Therapeutics ( NASDAQ: ATOS ) added ~17% to rise sharply for the second straight session on Wednesday after announcing that enrollment in a mid-stage trial for its experimental breast cancer therapy ( Z )-endoxifen reached 30%.
A selective estrogen receptor modulator (SERM) ( Z )-endoxifen is under investigation as a neoadjuvant option for certain patients with estrogen receptor-positive (ER+) invasive breast cancer.
Out of 20 patients expected to enroll in the trial’s ( Z )-endoxifen arm, the investigators have already dosed six patients, the company said.
The I-SPY 2 Phase 2 clinical trial represents a collaboration among multiple partners, including the U.S. Food and Drug Administration (FDA) and the Foundation for the National Institutes of Health (FNIH) Cancer Biomarkers Consortium.
"Reaching 30% enrollment in the I-SPY 2 study is another important milestone in our ambitious ( Z )-endoxifen development program," Atossa ( ATOS ) CEO Steven Quay remarked.
The company intends to use data from I-SPY 2 and its ongoing EVANGELINE trial to support interactions with the FDA and design a Phase 3 protocol.
More on Atossa
- Atossa Therapeutics launches up to $10M share repurchase program
- Atossa Therapeutics: Still Gets An 'Incomplete' Rating
For further details see:
Atossa jumps 17% after update on mid-stage trial for breast cancer drug